NEW YORK (GenomeWeb) – Epistem announced this week the completion of the management buyout of Genedrive following an undisclosed investment by Foresight Group. Epistem provides preclinical and clinical research services across specialist therapeutic areas, such as oncology, gastrointestinal diseases, and toxicity and inflammatory diseases. Foresight's investment will enable Epistem to expand its next-generation sequencing and laser-capture technologies, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.